Full Press Release Details
Director, Investor Relations & Corporate Strategy &
Glaukos Announces Preliminary, Unaudited
Fourth Quarter and Full Year 2020 Net Sales
San Clemente, CA - January 13, 2021 - Glaukos
Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment
of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter
and full year ended December 31, 2020.
Preliminary and unaudited total net sales for the fourth quarter
of 2020 are expected to be approximately $73 million, consisting of approximately $58 million in Glaucoma net sales and approximately
$15 million in Corneal Health net sales.
Preliminary and unaudited total net sales for the full year
of 2020 are expected to be approximately $225 million, consisting of approximately $179 million in Glaucoma net sales and approximately
$46 million in Corneal Health net sales.
"I am extremely proud of our teams' steadfast dedication
and resiliency to advance our key strategic priorities and execute our plans while navigating the unique challenges associated
with the COVID-19 pandemic over the course of 2020 into 2021. I also want to express my appreciation to our customers around the
world who continue to prioritize serving the needs of patients," said Thomas Burns, Glaukos president and chief executive
officer. "While we maintain near-term caution as uncertainties associated with COVID-19 persist, I am confident in our execution
and the longer-term fundamental prospects of our business remain strong as we advance our mission to transform the treatment of
chronic eye diseases."
These preliminary and unaudited net sales results are subject
to revision until the company provides its full financial and operating results in its upcoming earnings release and earnings call
for the fourth quarter of 2020, which is expected to be in late February.
Glaukos (www.glaukos.com) is an ophthalmic medical technology
and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The
company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management
paradigm. Glaukos launched the iStent , its first MIGS device, in the United States in July 2012, its next-generation
iStent inject device in the United States in September 2018, and most recently, the iStent inject W device
in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed
to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic
disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary
portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
Forward-Looking Statements
All statements other than statements of historical facts included
in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in
the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained
herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties
and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond
our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements
in this press release. These potential risks and uncertainties include, without limitation, uncertainties regarding the duration
and severity of the COVID-19 pandemic and its impact on our business or the economy generally and risks related to the commercialization
of new products, such as risks associated with product pricing, marketing and sales efforts. These and other risks, uncertainties
and factors related to Glaukos and our business are described in detail under the caption "Risk Factors" and elsewhere
in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the Securities and Exchange Commission
on November 5, 2020. All forward-looking statements included in this press release are expressly qualified in their entirety by
the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press
release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking
statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities
Further, the preliminary financial results for the company's
fourth quarter 2020 included in this press release represent the most current information available to management. The company's
actual results may differ from these preliminary results due to the completion of the company's financial closing procedures,
final adjustments, completion of the review by the company's independent registered public accounting firm and other developments
that may arise between the date of this press release and the time that financial results for the fourth quarter of 2020 are finalized.
Our filings with the SEC are available in the Investor Section
of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products
is available on our website at www.glaukos.com.